Results 191 to 200 of about 203,196 (295)

From mutational signatures to practice: Artificial intelligence-guided repurposing for blast crisis chronic myeloid leukemia. [PDF]

World J Clin Oncol
Karmakar R, Kandalkar A, Wang HC, Mukundan A.   +3 more
europepmc   +1 more source

Improved survival after acute graft-versus-host disease diagnosis in the modern era [PDF]

, 2017
et al.,, Hayashi, Robert J, Vig, Ravi
core   +1 more source

Introducing a prognostic score for successful treatment‐free remission in chronic myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary The modern management of chronic myeloid leukaemia (CML) identifies a new therapeutic goal of treatment‐free remission (TFR). Half of CML patients in durable deep molecular response (DMR) (MR4 or better) can remain off tyrosine kinase inhibitors (TKIs) without experiencing loss of major molecular response.
Simone Claudiani, Silvia Metelli, Afzal Khan, Guy Hannah, Jenny Byrne, Paolo Gallipoli, Simon J. Bulley, Gillian A. Horne, Kate Rothwell, Mhairi Copland, Richard E. Clark, Fiona Fernando, Andrew J. Innes, Jane F. Apperley, Dragana Milojkovic   +14 more
wiley   +1 more source

Biological Features of KLC2 Mutations in Chronic Myeloid Leukemia and Their Contribution to Inducing Drug Resistance. [PDF]

Oncol Res
Bera R, Ochi Y, Huang YJ, Kuo MC, Yoshida K, Ogawa S, Shih LY.   +6 more
europepmc   +1 more source

Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study

British Journal of Haematology, EarlyView.
Summary Teenage and young adult (TYA) patients undergoing allogeneic stem cell transplant have distinct psychosocial needs, yet they are poorly represented in research and their outcomes are not well understood. This study uses prospectively collected data from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT ...
Graham McIlroy, Ben Carpenter, Rachael Hough, Beki James, Caroline Besley, Emma Nicholson, Persis Amrolia, Oana Mirci‐Danicar, Caroline L. Furness, Brenda Gibson, Victoria Potter, Rachel Pearce, Julia Lee, Clementina Abamba, Anna Castleton, Ram Malladi   +15 more
wiley   +1 more source

Olverembatinib in chronic myeloid leukemia: is less actually better? [PDF]

Haematologica
Perusini MA, Kim DDH.
europepmc   +1 more source

Chemotherapy‐driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Chemotherapy‐induced WNT ligand secretion by bone marrow (BM) stroma drives acute lymphoblastic leukaemia (ALL) chemoresistance. WNT pathway inhibition disrupts this cross‐talk and restores therapeutic response, highlighting WNT inhibitors as a promising strategy to prevent relapse in ALL.
Foteini Kalampalika, Amanda Jiménez‐Pompa, Raúl Sánchez‐Lanzas, Bela Patel, Miguel Ganuza   +4 more
wiley   +1 more source

Population Pharmacokinetics of Radotinib in Healthy Volunteers and Patients with Chronic Myeloid Leukemia. [PDF]

Pharmaceuticals (Basel)
Kang M, Kim J, Lee Y, Shin JS, Park MS, Jiang Q, Chung EK, Lee JI.   +7 more
europepmc   +1 more source

Proteomic profile of CSF obtained at the time of diagnosis determines amyotrophic lateral sclerosis progression and survival: CXCL7 levels in disease prognosis and survival

Brain Pathology, EarlyView.
Untargeted multiomic profiling of cerebrospinal fluid reveals that proteomic, but not lipidomic, signatures robustly distinguish ALS patients from controls and stratify individuals by survival, highlighting marked molecular differences between short survival and long survival disease.
Sergio Roca‐Pereira, Yaiza López‐Sampere, Pol Mengod‐Soler, Mario Peña‐Fonteboa, Carla Marco, Alejandro Caravaca‐Puchades, Raúl Domínguez, Juan Francisco Vázquez‐Costa, Enrique Santamaría, Joaquín Fernández‐Irigoyen, María J. Colomina, Isabel León Moreno, Antonio Martínez Yélamos, Sergio Martínez Yélamos, Gabriel Santpere, Elia Obis, Manuel Portero‐Otín, Gerard Piñol‐Ripoll, Mónica Povedano, Pol Andrés‐Benito   +19 more
wiley   +1 more source

Improvement in survival of patients with higher risk but not lower risk myelodysplastic syndromes over 20 years: A retrospective study from Nagasaki, Japan

British Journal of Haematology, EarlyView.
Takafumi Furumoto, Koji Ando, Eo Toriyama, Tomoko Hata, Hikaru Sakamoto, Masahiko Chiwata, Hideaki Kitanosono, Jun Nakashima, Takeharu Kato, Masataka Taguchi, Makiko Horai, Hidehiro Itonaga, Shinya Sato, Yasushi Sawayama, Daisuke Imanishi, Yoshitaka Imaizumi, Tatsuro Jo, Shinichiro Yoshida, Yukiyoshi Moriuchi, Yasushi Miyazaki   +19 more
wiley   +1 more source